NCT00683995已完成3 期
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 43
研究概览
简要总结
This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent to participate in the study on a voluntary basis.
- •Patients who have been eligible for the confirmatory trial by meeting the inclusion criteria applicable at the time of giving written informed consent and those applicable at the time of randomization, and who have completed the confirmatory trial.
- •Outpatients who live with a caregiver such as a family member, or inpatients.
- •Require rescue medication at least 0.5 times (at least once every two days) but not more than three times per day on average as determined by the investigator.
- •Performance Status (ECOG) of 3 or less at the time of giving written informed consent.
- •Have a life expectancy of at least three months as determined by the investigator.
- •Be able to receive diary training and have been able to properly complete diaries during the confirmatory trial.
排除标准
- •Have experienced intolerable adverse reactions (as defined in Attachment 3) during the confirmatory trial.
- •Have met any of the exclusion criteria applicable at the time of giving written informed consent, those applicable at the time of randomization, or subject withdrawal criteria in the confirmatory trial.
- •Serious respiratory dysfunction.
- •Serious bradyarrhythmia.
- •Serious hepatic dysfunction.
- •Serious renal dysfunction.
- •Susceptibility to respiratory depression due to conditions such as increased intracranial pressure, head injury and brain tumor.
- •Patients who have a history of clinically significant adverse reactions to the combination of opioid analgesics and any of the following drugs/substances, and who are currently receiving or expect to receive any of them during the study:
- •Central nervous system depressants (phenothiazines, benzodiazepines and barbiturates), inhalation anesthetics, monoamine oxidase inhibitors, tricyclic antidepressants, skeletal muscle relaxants, antihistamines, ritonavir, alcohol, itraconazole, amiodarone, clarithromycin, diltiazem, and fluvoxamine.
- •History of convulsive seizures (except a single episode of infantile febrile convulsions).
- •History of hypersensitivity to fentanyl.
- •Pregnant or lactating women, possibly pregnant women, or women who are planning to become pregnant.
- •Patients who are judged by the investigator/subinvestigator to be inappropriate for this study.
研究组 & 干预措施
1
Experimental
KW-2246 (fentanyl citrate)
干预措施: KW-2246 (fentanyl citrate) (Drug)
研究者
相似试验
已完成
3 期
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer PatientsPain, CancerNCT00684632Kyowa Kirin Co., Ltd.51
已完成
3 期
A Comparative Study of KW-2246Cancer Related Pain (Breakthrough Pain)NCT01326689Kyowa Kirin Co., Ltd.42
未知
3 期
A phase III study of KW-2246JPRN-jRCT2080221423Kyowa Hakko Kirin Co., Ltd.
已完成
3 期
Long-Term Safety Study of KW-6500 in Patients With Parkinson's DiseaseParkinson's DiseaseNCT00955318Kyowa Kirin Co., Ltd.58
已完成
3 期
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in KoreaModerate to Severe Plaque PsoriasisNCT02982005Kyowa Kirin Korea Co., Ltd.62